- 作者：Ngoc-Anh Le ; Monica Farkas-Epperson ; Mary Ellen Sweeney ; Peter W.F. Wilson ; W. Virgil Brown
- 关键词：ABT-335 ; Fenofibric acid ; Metabolic syndrome ; Postprandial lipemia ; Oxidative susceptibility
- 刊名：Atherosclerosis
- 出版年：December, 2013
- 年：2013
- 卷：231
- 期：2
- 页码：268-273
- 全文大小：352 K
Objective
Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu++-mediated oxidation in patients with metabolic syndrome.Methods and results
This is a randomized double-blind, placebo-controlled study with cross-over and includes a 4-week wash-out period between the two treatment periods. At the end of each 8-week treatment period, subjects were challenged with a standardized mixed meal followed by blood collection over the ensuing 6聽h. Plasma lipoproteins were isolated by a combination of ultracentrifugation and FPLC for the continuous monitoring of conjugated dienes formation as an assessment of oxidative susceptibility. Fasting plasma TG was reduced by 20% (p聽<聽0.0002) and there was a modest reduction in hsCRP (6.1%, p聽<聽0.06). There was no change in either HDLc or LDLc in these subjects. Postprandial lipemia was reduced with ABT-335 as demonstrated by a 28.5% reduction (p聽<聽0.0005) in incremental area under the curve for TG during the 6-h聽period after the meal challenge. Lag times for both fasting LDL (+16%) and postprandial LDL (+28%) were increased with the ABT-335 therapy, suggestive of reduced oxidative susceptibility. Co-incubation with autologous HDL did not reduced LDL oxidative susceptibility in these patients.
Conclusion
ABT-335 therapy reduced fasting and postprandial triglycerides in patients with metabolic syndrome. Autologous HDL may be dysfunctional in these patients as co-incubation with HDL failed to reduce oxidative susceptibility of LDL. During ABT-335 therapy, LDL was less susceptible to Cu++-mediated oxidative modification, in spite of the lack of changes in LDLc levels.